StreetInsider.com News Articles

ArriVent reports 44.8% response rate for ADC ARR-217 in CRC patients

Sun, 25 Oct 2026 09:00:19 -0400

ArriVent BioPharma, Inc. (Nasdaq: AVBP) reported initial Phase 1 data for ARR-217, a cadherin-17 (CDH17)-targeted antibody-drug conjugate (ADC), in patients with gastrointestinal cancers, according to a press release. The findings were presented at the 2026 European Society for Medical Oncology (ESMO) Congress.

The ongoing multicenter, open-label Phase 1 study evaluated ARR-217 in patients with unresectable, locally advanced, or metastatic solid tumors, with a focus on colorectal, pancreatic, and other gastrointestinal cancers. As of the August 5, 2026 data cutoff, 123 patients were treated across six dose levels ranging from 2 mg/kg to 8 mg/kg, including 113 patients with colorectal cancer (CRC).

ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026

Sun, 25 Oct 2026 09:00:00 -0400

44.8% ORR at 6mg/kg dose in late-line CRC patients
ARR-217 was generally well-tolerated
ArriVent to host virtual webinar on Monday, October 26, 2026, at 8 am ET to discuss the data from the ARR-217 program

NEWTOWN SQUARE, Pa., Oct. 25, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced initial encouraging Phase 1 results for ARR-217, (MRG007), a cadherin-17 (CDH17)-targeting antibody-drug conjugate (ADC) developed in partnership with Lepu Biopharma Co., Ltd., in

ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026

Sun, 25 Oct 2026 09:00:00 -0400

44.8% ORR at 6mg/kg dose in late-line CRC patients
ARR-217 was generally well-tolerated
ArriVent to host virtual webinar on Monday, October 26, 2026, at 8 am ET to discuss the data from the ARR-217 program

ArriVent to present phase 1 ADC data at ESMO Congress 2026

Fri, 23 Oct 2026 16:00:13 -0400

ArriVent BioPharma, Inc. (Nasdaq: AVBP) announced that initial Phase 1 safety and efficacy data for its CDH17-targeted antibody-drug conjugate ARR-217 will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.

The data, drawn from a first-in-human study (NCT07066657) in patients with locally advanced or metastatic gastrointestinal cancers, will be delivered as a rapid oral presentation on October 25, 2026, from 8:30 to 10:00 AM CEST under abstract number LBA34.

ARR-217, also known as MRG007, is a cadherin-17 (CDH17)-targeted ADC that uses a glycan-linked, exatecan-based payload. CDH17 is a cell adhesion molecule described as frequently overexpressed in

ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026

Fri, 23 Oct 2026 16:00:00 -0400

First-in-human data for ARR-217 selected as a late-breaking oral presentation
ArriVent to host virtual webinar on Monday, October 26, 2026, at 8 am ET to discuss the data from the ARR-217 program

NEWTOWN SQUARE, Pa., Oct. 23, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that initial safety and efficacy data from the Phase 1 (NCT07066657) study of CDH17-targeted ADC ARR-217 (MRG007) in patients with gastrointestinal cancers, will be presented in a rapid oral

ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026

Fri, 23 Oct 2026 16:00:00 -0400

First-in-human data for ARR-217 selected as a late-breaking oral presentation
ArriVent to host virtual webinar on Monday, October 26, 2026, at 8 am ET to discuss the data from the ARR-217 program

ArriVent BioPharma (AVBP) PT Lowered to $29 at B.Riley

Tue, 20 Oct 2026 09:07:23 -0400

B.Riley analyst Kalpit Patel lowered the price target on ArriVent BioPharma (NASDAQ: AVBP) to $29.00 (from $45.00) while maintaining a Buy rating.

Form 8-K ArriVent BioPharma, Inc. For: Oct 19

Mon, 19 Oct 2026 08:08:00 -0400

si-local-file:///var/storage/secattach/20261019/27201052.html

ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer

Mon, 19 Oct 2026 08:01:00 -0400

NEWTOWN SQUARE, Pa., Oct. 19, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the publication of FURTHER Phase 1b (FURMO-002; NCT05364073) results of firmonertinib in Cancer Cell, highlighting the preclinical and clinical findings supporting its potential, if approved, as the first oral, chemotherapy-free targeted therapy for treatment-naïve patients with advanced EGFR PACC-mutant non-small cell lung cancer (NSCLC).

EGFR PACC-mutant NSCLC is one of the largest underserved patient populations within EGFR-driven lung cancer.

ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer

Mon, 19 Oct 2026 08:01:00 -0400

EGFR PACC-mutant NSCLC is one of the largest underserved patient populations within EGFR-driven lung cancer.

ArriVent BioPharma (AVBP) PT Raised to $27 at Jefferies

Fri, 16 Oct 2026 06:07:02 -0400

Jefferies analyst Kelly Shi raised the price target on ArriVent BioPharma (NASDAQ: AVBP) to $27.00 (from $18.00) while maintaining a Buy rating.

Form SCHEDULE 13G ArriVent BioPharma, Inc. Filed by: Vivo Opportunity Fund Holdings, L.P.

Tue, 13 Oct 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20261013/27181019.html

Form 8-K ArriVent BioPharma, Inc. For: Oct 12

Tue, 13 Oct 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20261013/27176322.html

ArriVent doses first patient in Phase 1 trial of ADC ARR-002

Mon, 12 Oct 2026 16:03:04 -0400

ArriVent BioPharma, Inc. (Nasdaq: AVBP) announced that the first patient has been dosed in a Phase 1 clinical trial in the U.S. with ARR-002, a dual-target antibody-drug conjugate (ADC) being studied for ovarian and endometrial cancer.

ARR-002 is described by the company as a potential first-in-class MUC16/NaPi2b dual-target tetravalent ADC. The trial, registered as NCT07755436, is designed to evaluate the safety, tolerability, efficacy, and pharmacokinetics of ARR-002 in patients with advanced or metastatic ovarian or endometrial cancer.

Stuart Lutzker, MD, Ph.D., President of Research and Development at ArriVent, said the dual-targeting approach of ARR-002 "is designed to overcome a key limitation of

ArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002

Mon, 12 Oct 2026 16:01:00 -0400

NEWTOWN SQUARE, Pa., Oct. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that it dosed its first patient in the Phase 1 trial in the U.S. with ARR-002 (NCT07755436), a potential first-in-class MUC16/NaPi2b dual-target tetravalent antibody-drug conjugate (ADC) for ovarian and endometrial cancer.

“We are pleased to have dosed our first patient with ARR-002, our second ADC from our portfolio to enter the clinic,” said Stuart Lutzker, MD, Ph.D., President of

ArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002

Mon, 12 Oct 2026 16:01:00 -0400

“We are pleased to have dosed our first patient with ARR-002, our second ADC from our portfolio to enter the clinic,” said Stuart Lutzker, MD, Ph.D., President of

Form SCHEDULE 13D/A ArriVent BioPharma, Inc. Filed by: ORBIMED ADVISORS LLC

Thu, 08 Oct 2026 18:40:00 -0400

si-local-file:///var/storage/secattach/20261008/27167928.html

ArriVent BioPharma (AVBP) PT Lowered to $27 at H.C. Wainwright

Thu, 08 Oct 2026 07:10:28 -0400

(Updated - October 8, 2026 7:10 AM EDT)

H.C. Wainwright analyst Robert Burns lowered the price target on ArriVent BioPharma (NASDAQ: AVBP) to $27.00 (from $47.00) while maintaining a Buy rating.

The analyst commented: "FURVENT trial narrowly misses PFS primary endpoint. Earlier this week, ArriVent announced that the Phase 3 FURVENT trial (NCT05607550), which compared firmonertinib against platinum-based chemo + pemetrexed in 1L EGFR ex20ins+ NSCLC patients, failed to meet its PFS primary endpoint because the control arm outperformed; recall, FURVENT was powered to detect a three-month mPFS difference between firmonertinib and the control arm, with the expectation that firmonertinib and the

ArriVent BioPharma (AVBP) PT Lowered to $27 at H.C. Wainwright

Thu, 08 Oct 2026 07:10:28 -0400

(Updated - October 8, 2026 7:10 AM EDT)

H.C. Wainwright analyst Robert Burns lowered the price target on ArriVent BioPharma (NASDAQ: AVBP) to $27.00 (from $47.00) while maintaining a Buy rating.

ArriVent BioPharma (AVBP) PT Lowered to $18 at Guggenheim

Wed, 07 Oct 2026 07:33:53 -0400

Guggenheim analyst Michael Schmidt lowered the price target on ArriVent BioPharma (NASDAQ: AVBP) to $18.00 (from $45.00) while maintaining a Buy rating.

ArriVent BioPharma (AVBP) PT Lowered to $18 at Truist Securities

Wed, 07 Oct 2026 07:13:11 -0400

Truist Securities analyst Supawat Thongthip lowered the price target on ArriVent BioPharma (NASDAQ: AVBP) to $18.00 (from $45.00) while maintaining a Buy rating.

ArriVent BioPharma (AVBP) PT Lowered to $29 at BTIG

Wed, 07 Oct 2026 05:03:16 -0400

BTIG analyst Jeet Mukherjee lowered the price target on ArriVent BioPharma (NASDAQ: AVBP) to $29.00 (from $42.00) while maintaining a Buy rating.

The analyst comments "We were ultimately mistaken on our call for FURVENT, having not fully accounted for the difference between investigator vs. BICR PFS reads that drove chemo arm outperformance in this trial. With FURVENT in the rearview now, our discussions with investors revolve around the stock at a new entry point and the upcoming ARR-217/CDH17 data at ESMO. We anticipate a ~20% ORR across doses and ~25% ORR at potential go forward doses in mCRC would be perceived

ArriVent BioPharma (AVBP) PT Lowered to $29 at BTIG

Wed, 07 Oct 2026 05:03:16 -0400

BTIG analyst Jeet Mukherjee lowered the price target on ArriVent BioPharma (NASDAQ: AVBP) to $29.00 (from $42.00) while maintaining a Buy rating.

ArriVent stock tumbles 60% after trial misses primary endpoint

Tue, 06 Oct 2026 08:45:36 -0400

Investing.com -- ArriVent BioPharma (NASDAQ:AVBP) shares fell 63% Tuesday after the company announced its Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion mutant non-small cell lung cancer failed to meet its primary endpoint.

The trial, which evaluated firmonertinib monotherapy in patients with previously untreated, locally advanced or metastatic non-squamous NSCLC harboring EGFR exon 20 insertion mutations, did not achieve its primary endpoint of progression free survival by blinded independent central review. The study compared firmonertinib at 160 mg and 240 mg doses against platinum-based chemotherapy with pemetrexed.

According to the results, median PFS by BICR was 11.0

Form 8-K ArriVent BioPharma, Inc. For: Oct 06

Tue, 06 Oct 2026 08:07:00 -0400

si-local-file:///var/storage/secattach/20261006/27152311.html